Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Status:
Terminated
Trial end date:
2020-06-14
Target enrollment:
Participant gender:
Summary
For patients with "Platinum-resistant recurrent ovarian cancer" after second-line
chemotherapy failure Using apatinib as a single drug Clinical efficacy observation Single
study no control
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University